Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Inclusion Criteria

• ECOG PS 0 or 1
• HLA-A*02:01 positive
• PRAME positive tumor
• Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies
• If applicable, must agree to use highly effective contraception

Exclusion Criteria

• Symptomatic or untreated central nervous system metastasis
• Recent bowel obstruction
• Ongoing ascites or effusion requiring recent drainages
• Significant immune-mediated adverse event with prior immunotherapy (Participants in checkpoint inhibitor combination treatment)
• Inadequate washout from prior anticancer therapy
• Significant ongoing toxicity from prior anticancer treatment
• Out-of-range laboratory values
• Clinically significant lung, heart, or autoimmune disease
• Ongoing requirement for immunosuppressive treatment
• Prior solid organ or bone marrow transplant
• Active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection
• Significant secondary malignancy
• Hypersensitivity to study drug or excipients
• Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study intervention
• Pregnant or lactating participants
• Any other contraindication for applicable combination partner based on local prescribing information